Ligand Pharmaceuticals Income Statement

Financials in millions CAD. Fiscal year is March - February.

Millions CAD. Fiscal year is Mar - Feb.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	May '25 May 31, 2025	Feb '25 Feb 28, 2025	Feb '24 Feb 29, 2024	Feb '23 Feb 28, 2023	Feb '22 Feb 28, 2022
Revenue	0.14	0.12	0.12	0.17	0.1
Revenue Growth (YoY)	41.22%	-3.73%	-27.72%	70.64%	-
Cost of Revenue	0.05	0.05	0.06	0.12	0.04
Gross Profit	0.09	0.07	0.06	0.05	0.06
Selling, General & Admin	0.2	0.27	0.51	0.92	0.44
Research & Development	-	-	0.12	-	-
Operating Expenses	0.2	0.27	0.81	0.96	0.47
Operating Income	-0.11	-0.2	-0.75	-0.91	-0.4
Interest Expense	-	-	-0.09	-0.07	-0.02
Other Non Operating Income (Expenses)	-0.01	-0.01	-0.21	-0.03	-
EBT Excluding Unusual Items	-0.12	-0.22	-1.05	-1.01	-0.42
Impairment of Goodwill	-	-	-	-0.86	-
Gain (Loss) on Sale of Investments	-	-	-	-0.31	-
Asset Writedown	-	-	-0.37	-0.65	-
Other Unusual Items	-	-	0.02	-0.26	-
Pretax Income	-0.12	-0.22	-1.41	-3.09	-0.42
Income Tax Expense	-	-	-0.01	-0.01	-0.14
Net Income	-0.12	-0.22	-1.4	-3.08	-0.28
Net Income to Common	-0.12	-0.22	-1.4	-3.08	-0.28
Shares Outstanding (Basic)	108	111	100	82	44
Shares Outstanding (Diluted)	108	111	100	82	44
Shares Change (YoY)	3.99%	12.00%	21.38%	88.09%	-
EPS (Basic)	-0.00	-0.00	-0.01	-0.04	-0.01
EPS (Diluted)	-0.00	-0.00	-0.01	-0.04	-0.01
Gross Margin	65.25%	58.27%	47.63%	30.49%	63.89%
Operating Margin	-76.09%	-170.38%	-612.59%	-533.41%	-405.39%
Profit Margin	-85.93%	-182.32%	-1136.63%	-1809.57%	-278.57%
EBITDA	-	-	-0.74	-0.89	-0.39
D&A For EBITDA	-	-	0.01	0.01	0.01
EBIT	-0.11	-0.2	-0.75	-0.91	-0.4
EBIT Margin	-76.09%	-170.38%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.